SML0700
FTY720
≥98% (HPLC), powder, sphingosine 1-phosphate receptor modulator
Synonym(s):
2-Amino-2-[2-(4-octyl-phenyl)-ethyl]-propane-1,3-diol hydrochloride, Fingolimod hydrochloride
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C19H33NO2 · HCl
CAS Number:
Molecular Weight:
343.93
UNSPSC Code:
12352211
NACRES:
NA.77
Product Name
FTY720, ≥98% (HPLC)
SMILES string
Cl.NC(CO)(CO)CCc1ccc(cc1)CCCCCCCC
InChI
1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H
InChI key
SWZTYAVBMYWFGS-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
water: 10 mg/mL, clear
storage temp.
−20°C
Quality Level
Looking for similar products? Visit Product Comparison Guide
Application
FTY720 has been used as an immunomodulator and is used to investigate its effect on in vitro gastrulation model of P19C5 stem cells. It is also used to determine its efficacy in prolonging the survival corneal transplantation. FTY720 has been used to study its effect on the proliferation and differentiation of cultured embryonic hippocampal neural stem cells (NSCs) using the 5-bromo-2-deoxyuridine incorporation assay, the neurosphere formation assay and western blot analysis.
Biochem/physiol Actions
FTY720 is an immunomodulating drug and sphingosine 1-phosphate (S1P) receptor modulator. Phosphorylation of FTY270 by sphingosine kinase causes S1P1R internalization, which sequesters lymphocytes in lymph nodes, preventing them from taking part in an autoimmune response. Clinically, it has been approved for the treatment of multiple sclerosis (MS). It has also been shown to block and reverse paclitaxel-induced chemotherapy induced peripheral neuropathy (CIPN) through S1PR inhibition as well as inhibit the activity of histone deacetylases in the hippocampus of mouse brains, thereby modulating memory.
FTY720, an immunomodulating drug, acts as a sphingosine 1-phosphate (S1P) receptor modulator.
signalword
Warning
hcodes
pcodes
Hazard Classifications
STOT RE 2
target_organs
Immune system
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Veronique E Miron et al.
Journal of the neurological sciences, 274(1-2), 13-17 (2008-08-06)
FTY720, also known as fingolimod, is an orally administered sphingosine-1-phosphate (S1P) analogue that is under investigation as a therapy for both relapsing-remitting (RR) and progressive forms of multiple sclerosis (MS). The demonstrated beneficial effect of FTY720 on disease activity in
Mohammad G Mohammad et al.
The Journal of clinical investigation, 124(3), 1228-1241 (2014-02-27)
In the CNS, no pathway dedicated to immune surveillance has been characterized for preventing the anti-CNS immune responses that develop in autoimmune neuroinflammatory disease. Here, we identified a pathway for immune cells to traffic from the brain that is associated
Darren Ruane et al.
The Journal of experimental medicine, 210(9), 1871-1888 (2013-08-21)
Developing efficacious vaccines against enteric diseases is a global challenge that requires a better understanding of cellular recruitment dynamics at the mucosal surfaces. The current paradigm of T cell homing to the gastrointestinal (GI) tract involves the induction of α4β7
Douglas Kazutoshi Sato et al.
Journal of neuroimmunology, 268(1-2), 95-98 (2014-02-11)
Fingolimod has demonstrated efficacy in patients with multiple sclerosis (MS), and patients become gradually lymphopenic after a few days of treatment, with selective reductions in CD4+ subsets. We observed an increase in the frequencies of circulating regulatory T cells after
Goeril Karlsson et al.
Neurology, 82(8), 674-680 (2014-01-28)
To report outcomes of pregnancies that occurred during the fingolimod clinical development program. Pregnancy outcomes from phase II, phase III, and phase IV clinical studies (with optional extensions) were reported by clinical trial investigators. Fingolimod exposure in utero was defined
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service